期刊
JOURNAL OF CANCER
卷 12, 期 4, 页码 1011-1022出版社
IVYSPRING INT PUBL
DOI: 10.7150/jca.48310
关键词
apoptosis; autophagy; BIX-01294; diffuse large B cell lymphoma; endoplasmic reticulum stress
类别
资金
- National Natural Science Foundation of China [81700199, 81500121]
- Natural Science Foundation of Jiangsu Province [BK20170257, BK20171181]
- Jiangsu Provincial Key Research and Development Program [BE2017638]
- Natural Science Foundation of the Jiangsu Higher Education Institutions of China [17KJB320019]
- China Postdoctoral Science Foundation [2017M611917, 2016M601891]
- Jiangsu Planned Projects for Postdoctoral Research Funds [1601099C, 1701134C]
This study demonstrates that BIX-01294 can inhibit DLBCL cell proliferation, induce apoptosis and autophagy through various pathways, making it a potential therapeutic drug for DLBCL.
Despite advancement in the treatment of diffuse large B-cell lymphoma (DLBCL), many patients tend to relapse or become refractory after initial therapy. Therefore, it is essential to identify novel therapeutic targets and drugs, understand the molecular pathogenesis mechanism of DLBCL, and find ways to prevent and treat relapsed or refractory DLBCL. BIX-01294 is a small molecule compound that specifically inhibits EHMT2 activity. In this study, we demonstrate that BIX-01294 triggered the inhibition of human DLBCL cell proliferation, lead to G(1) phase arrest via increasing P21 level and reducing cyclin E level. BIX-01294 also induced apoptosis via endogenous and exogenous apoptotic pathways. Moreover, BIX-01294 triggered autophagy and activated ER stress in human DLBCL cells. Furthermore, we showed that both key components of ER stress, ATF3, and ATF4, are required for BIX-01294-induced apoptosis and autophagy. Hence, this study provides new evidence that EHMT2 may be a new therapeutic target, and BIX-01294 may be a potential therapeutic drug for treating DLBCL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据